| Literature DB >> 28039895 |
M Shagrani1,2, J Burkholder1, D Broering1, M Abouelhoda3,4, T Faquih3,4, M El-Kalioby3,4, S N Subhani3,4, E Goljan3,4, R Albar3, D Monies3,4, N Mazhar3, B S AlAbdulaziz3, K A Abdelrahman3, N Altassan3,4, F S Alkuraya3,4,5.
Abstract
Advanced cholestatic liver disease is a leading referral to pediatric liver transplant centers. Recent advances in the genetic classification of this group of disorders promise a highly personalized management although the genetic heterogeneity also poses a diagnostic challenge. Using a next-generation sequencing-based multi-gene panel, we performed retrospective analysis of 98 pediatric patients who presented with advanced cholestatic liver disease. A likely causal mutation was identified in the majority (61%), spanning many genes including ones that have only rarely been reported to cause cholestatic liver disease, e.g. TJP2 and VIPAS39. We find no evidence to support mono-allelic phenotypic expression in the carrier parents despite the severe nature of the respective mutations, and no evidence of oligogenicity. The high-carrier frequency of the founder mutations identified in our cohort (1 in 87) suggests a minimum incidence of 1:7246, an alarmingly high disease burden that calls for the primary prevention through carrier screening.Entities:
Keywords: cholestasis; personalized medicine; tight-junction; transplant
Mesh:
Substances:
Year: 2017 PMID: 28039895 DOI: 10.1111/cge.12959
Source DB: PubMed Journal: Clin Genet ISSN: 0009-9163 Impact factor: 4.438